Related Experiment Video
Updated: Nov 28, 2025
08:46
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
53.8K
A Primer on Chimeric Antigen Receptor T-cell Therapy: What Does It Mean for Pathologists?
Allison M Cushman-Vokoun1, Karl V Voelkerding2, Mark K Fung3
1From the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha (Cushman-Vokoun).
Archives of Pathology & Laboratory Medicine
|November 25, 2020
Summary
Chimeric antigen receptor T-cell (CAR-T) therapy shows promise in treating cancers. This guidance paper educates pathologists on CAR-T, emphasizing their crucial role in its clinical application and monitoring.
Area of Science:
- Immunotherapy
- Cellular Therapy
- Oncology
Background:
- Chimeric antigen receptor T-cell (CAR-T) technology demonstrates significant antitumor potential in preclinical and clinical settings.
- FDA-approved CAR-T therapies for B-cell malignancies are integrating into standard clinical practice.
Purpose of the Study:
- To educate pathologists on CAR-T therapy and its regulatory landscape.
- To clarify the role of pathologists in the administration and monitoring of CAR-T treatments.
- To advocate for pathologist involvement in emerging cellular therapies.
Main Methods:
- Convening of a CAR-T workgroup by the College of American Pathologists.
- Development of a summary guidance paper for the Council on Scientific Affairs.
- Identification of knowledge gaps among pathologists regarding CAR-T therapy.
Main Results:
- Pathologists expressed uncertainty regarding the clinical laboratory's role in supporting CAR-T therapy.
- The workgroup identified key areas for pathologist education and engagement.
- Findings aim to empower pathologists as stakeholders in CAR-T therapy administration.
Conclusions:
- This manuscript provides essential education on CAR-T therapy for pathologists.
- It initiates discussions on CAR-T science, clinical applications, and regulatory considerations.
- Pathologist engagement is vital as CAR-T therapies become more prevalent.
